Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss

被引:10
作者
Crepeau, Philip [1 ]
Chen, Xiaomeng [1 ]
Udyavar, Rhea [1 ]
Morris-Wiseman, Lilah F. [1 ]
Segev, Dorry L. [2 ,3 ]
McAdams-DeMarco, Mara [2 ,3 ]
Mathur, Aarti [1 ]
机构
[1] Johns Hopkins Univ, Dept Surg, Sch Med, 600 North Wolfe St,Blalock 606, Baltimore, MD 21287 USA
[2] NYU, Dept Surg, Grossman Sch Med, New York, NY 10003 USA
[3] Langone Hlth, New York, NY USA
关键词
PARATHYROID-HORMONE LEVELS; TERTIARY HYPERPARATHYROIDISM; RENAL-TRANSPLANTATION; RISK-FACTOR; MANAGEMENT; SECONDARY; PREVALENCE; METABOLISM; SOCIETY;
D O I
10.1016/j.surg.2022.07.031
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Hyperparathyroidism persists in many patients after kidney transplantation. The purpose of this study was to evaluate the association between post-transplant hyperparathyroidism and kidney transplantation outcomes. Methods: We identified 824 participants from a prospective longitudinal cohort of adult patients who underwent kidney transplantation at a single institution between December 2008 and February 2020. Parathyroid hormone levels before and after kidney transplantation were abstracted from medical records. Post-transplant hyperparathyroidism was defined as parathyroid hormone level >= 70 pg/mL 1 year after kidney transplantation. Cox proportional hazards models were used to estimate the adjusted hazard ratios of mortality and death-censored graft loss by post-transplant hyperparathyroidism. Models were adjusted for age, sex, race/ethnicity, college education, parathyroid hormone level before kidney transplantation, cause of kidney failure, and years on dialysis before kidney transplantation. A Wald test for interactions was used to evaluate the risk of death-censored graft loss by age, sex, and race. Results: Of 824 recipients, 60.9% had post-transplant hyperparathyroidism. Compared with nonhyperparathyroidism patients, those with post-transplant hyperparathyroidism were more likely to be Black (47.2% vs 32.6%), undergo dialysis before kidney transplantation (86.9% vs 76.6%), and have a parathyroid hormone level >= 300 pg/mL before kidney transplantation (26.8% vs 9.5%) (all P <.001). Patients with post-transplant hyperparathyroidism had a 1.6-fold higher risk of death-censored graft loss (adjusted hazard ratio <1/4> 1.60, 95% confidence interval: 1.02e2.49) compared with those without posttransplant hyperparathyroidism. This risk more than doubled in those with parathyroid hormone >= 300 pg/mL 1 year after kidney transplantation (adjusted hazard ratio 1/4 4.19, 95% confidence interval: 1.95-9.03). The risk of death-censored graft loss did not differ by age, sex, or race (all P-interaction >.05). There was no association between post-transplant hyperparathyroidism and mortality. Conclusion: The risk of graft loss was significantly higher among patients with post-transplant hyperparathyroidism when compared with patients without post-transplant hyperparathyroidism. (c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:138 / 145
页数:8
相关论文
共 36 条
[21]   How Well Does Renal Transplantation Cure Hyperparathyroidism? [J].
Lou, Irene ;
Foley, David ;
Odorico, Scott K. ;
Leverson, Glen ;
Schneider, David F. ;
Sippel, Rebecca ;
Chen, Herbert .
ANNALS OF SURGERY, 2015, 262 (04) :653-659
[22]   The Effects of Mineral Metabolism Markers on Renal Transplant Outcomes [J].
Marcen, R. ;
Jimenez, S. ;
Fernandez, A. ;
Galeano, C. ;
Villafruela, J. J. ;
Burgos, F. J. ;
Quereda, C. .
TRANSPLANTATION PROCEEDINGS, 2012, 44 (09) :2567-2569
[23]   Big Data in Organ Transplantation: Registries and Administrative Claims [J].
Massie, A. B. ;
Kuricka, L. M. ;
Segev, D. L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (08) :1723-1730
[24]   Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes [J].
Mathur, Aarti ;
Sutton, Whitney ;
Ahn, JiYoon B. ;
Prescott, Jason D. ;
Zeiger, Martha A. ;
Segev, Dorry L. ;
McAdams-DeMarco, Mara .
TRANSPLANTATION, 2021, 105 (12) :E366-E374
[25]   Clinical Impact of Hypercalcemia in Kidney Transplant [J].
Messa, Piergiorgio ;
Cafforio, Cosimo ;
Alfieri, Carlo .
INTERNATIONAL JOURNAL OF NEPHROLOGY, 2011, 2011
[26]   Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice [J].
Muirhead, N. ;
Zaltman, J. S. ;
Gill, J. S. ;
Churchill, D. N. ;
Poulin-Costello, M. ;
Mann, V. ;
Cole, E. H. .
CLINICAL TRANSPLANTATION, 2014, 28 (02) :161-165
[27]  
National Kidney Foundation, 2003, Am J Kidney Dis, V42, pS1, DOI [10.1016/S0272-6386(03)00905-3, DOI 10.1016/S0272-6386(03)00905-3]
[28]   Cardiovascular manifestations of primary hyperparathyroidism: a narrative [J].
Pepe, Jessica ;
Cipriani, Cristiana ;
Sonato, Chiara ;
Raimo, Orlando ;
Biamonte, Federica ;
Minisola, Salvatore .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (06) :R297-R308
[29]   Increased Risk of All-Cause Mortality and Renal Graft Loss in Stable Renal Transplant Recipients With Hyperparathyroidism [J].
Pihlstrom, Hege ;
Dahle, Dag Olav ;
Mjoen, Geir ;
Pilz, Stefan ;
Maerz, Winfried ;
Abedini, Sadollah ;
Holme, Ingar ;
Fellstrom, Bengt ;
Jardine, Alan G. ;
Holdaas, Hallvard .
TRANSPLANTATION, 2015, 99 (02) :351-359
[30]   Secondary and Tertiary Hyperparathyroidism, State of the Art Surgical Management [J].
Pitt, Susan C. ;
Sippel, Rebecca S. ;
Chen, Herbert .
SURGICAL CLINICS OF NORTH AMERICA, 2009, 89 (05) :1227-+